And perhaps also another "potential" perspective to consider:
(i) Patient is presumed clear of infection from initial consultation (tele-health or in person) based on other products / existing approaches.
(ii) Condition of the patient deteriorates and they end up in an ER.
(ii) Doctor in the ER then rapidly diagnoses respiratory infection using ResApp and proper and prompt treatment is given (as expanding and implementing ResApp in emergency room settings was one of the many reasons for the recent CR...).
(iv) Medical industry (and consumers) realise (hopefully) the easiness and effectiveness of ResApp as a frontline diagnostic tool, thus avoiding timely, dangerous and avoidable misdiagnosis.
Just another perspective/scenario to consider....
- Forums
- ASX - By Stock
- Dr Keating Email Interview
And perhaps also another "potential" perspective to consider:...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online